This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

ArthroCare Reports Third Quarter 2012 Financial Results

Total operating expenses were $47.1 million in the third quarter of 2012 compared to $53.4 million in the third quarter of 2011. Exit costs decreased $2.8 million and investigation and restatement costs decreased $3.8 million in this quarter as compared to the third quarter of 2011. Sales and marketing expenses increased $1.4 million, to 31.2 percent of total revenues this quarter compared to 30.9 percent for the same quarter of 2011.

NET INCOME AVAILABLE TO COMMON STOCKHOLDERS

Earnings per share from continuing operations applicable to common stockholders was $0.27 per diluted share in the third quarter of 2012 compared to $0.05 per diluted share in the third quarter of 2011.

BALANCE SHEET AND CASH FLOWS

Cash and cash equivalents was $203.2 million as of September 30, 2012 compared to $219.6 million at December 31, 2011. In the first quarter of 2012, the Company paid $74 million as required under the proposed settlement of the private securities class actions. Excluding this payment, cash and cash equivalents increased $57.6 million during the nine months ended September 30, 2012. Cash used in operating activities for the nine months ended September 30, 2012 was $10.6 million compared to cash provided by operating activities of $69.8 million for the nine months ended September 30, 2011. Adjusting for the funding of the $74 million settlement of the private securities class actions, cash provided by operating activities in the first nine months of 2012 would have been $63.4 million.

CONFERENCE CALL

ArthroCare will hold a conference call with the financial community to present these results at 8:30 a.m. ET/5:30 a.m. PT on Thursday, November 1, 2012. To participate in the live conference call dial 855-724-2350. A live and on-demand webcast of the call will be available on ArthroCare’s Web site at www.arthrocare.com. A telephonic replay of the conference call can be accessed by dialing 800-633-8284 and entering pass code number 21609480. The replay will remain available through November 15, 2012.

ABOUT ARTHROCARE

ArthroCare develops and manufactures surgical devices, instruments, and implants that strive to enhance surgical techniques as well as improve patient outcomes. Its devices improve many existing surgical procedures and enable new minimally invasive procedures. Many of ArthroCare’s devices use its internationally patented Coblation ® technology. This technology precisely dissolves target tissue and limits damage to surrounding healthy tissue. ArthroCare also develops surgical devices utilizing other patented technology including its OPUS ® line of fixation products as well as re-usable surgical instruments. ArthroCare is leveraging these technologies in order to offer a comprehensive line of surgical devices to capitalize on a multi-billion dollar market opportunity across several surgical specialties, including its two core product areas consisting of Sports Medicine and Ear, Nose, and Throat as well as other areas such as spine, wound care, urology and gynecology.

FORWARD-LOOKING STATEMENTS

The information provided herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on beliefs and assumptions by management and on information currently available to management. Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update any of them publicly in light of new information or future events. Additional factors that could cause actual results to differ materially from those contained in any forward-looking statement include, without limitation: the resolution of litigation pending against the Company; the impact upon the Company’s operations of legal compliance matters which may require improvement and remediation; the ability of the Company to control expenses relating to legal or compliance matters; the Company’s ability to remain current in its periodic reporting requirements under the Exchange Act and to file required reports with the Securities and Exchange Commission on a timely basis; the results of the investigation being conducted by the United States Department of Justice; the impact on the Company of additional civil and criminal investigations by state and federal agencies and civil suits by private third parties involving the Company’s financial reporting and its previously announced restatement and its insurance billing and healthcare fraud-and-abuse compliance practices; the results of the civil investigation by the Department of Justice related to the Civil Investigative Demand we received arising under the False Claims Act; the possibility that the Department of Justice could institute civil proceedings against us, based on the results of the investigation related to the Civil Investigative Demand; the risk that we could be subject to qui tam suits involving the False Claims Act; the possibility that the Department of Justice could institute a criminal enforcement action against us based on the results of the civil investigation related to the Civil Investigative Demand; the resolution of any litigation related to the civil investigation; the ability of the Company to attract and retain qualified senior management and to prepare and implement appropriate succession planning for its Chief Executive Officer; general business, economic and political conditions; competitive developments in the medical devices market; changes in applicable legislative or regulatory requirements; the Company’s ability to effectively and successfully implement its business strategies, and manage the risks in its business; and the reactions of the marketplace to the foregoing.

   
 
ARTHROCARE CORPORATION
Condensed Consolidated Balance Sheets - Unaudited
(in thousands, except par value data)

September 30, 2012

December 31, 2011

 
ASSETS
Current assets:
Cash and cash equivalents $ 203,163 $ 219,605

Accounts receivable, net of allowances of $2,002 and $2,251 at September 30, 2012 and December 31, 2011, respectively

41,196 51,350
Inventories, net 49,591 35,761
Deferred tax assets 28,321 40,622
Prepaid expenses and other current assets   5,136     5,532  
Total current assets 327,407 352,870
 
Property and equipment, net 30,946 35,769
Intangible assets, net 2,685 5,457
Goodwill 119,924 119,159
Deferred tax assets 18,178 18,159
Other assets   2,064     1,587  
Total assets $ 501,204   $ 533,001  
 
LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 13,665 $ 15,258
Accrued liabilities 38,203 112,586
Deferred Revenue 451 742
Deferred tax liabilities 76 -
Income tax payable   -     1,542  
Total current liabilities 52,395 130,128
 
Deferred tax liabilities 296 29
Other non-current liabilities   18,976     18,922  
Total liabilities 71,667 149,079
 

Commitments and contingencies (Notes 6 and 7)

 

Series A 3% Redeemable Convertible Preferred Stock, par value $0.001; Authorized: 100 shares;

Issued and outstanding: 75 shares at September 30, 2012 and December 31, 2011; Redemption

value: $87,089

79,850 77,184
 
Stockholders' equity:
Preferred stock, par value $0.001; Authorized: 4,900 shares; Issued and outstanding: none - -
Common stock, par value $0.001; Authorized: 75,000 shares; Issued: 31,801 and 31,523 shares
Outstanding: 27,851 and 27,562 shares at September 30, 2012 and December 31, 2011, respectively 28 28
Treasury stock: 3,950 and 3,968 shares at September 30, 2012 and December 31, 2011, respectively (106,645 ) (107,126 )
Additional paid-in capital 409,942 400,580
Accumulated other comprehensive income 5,180 4,615
Retained earnings   41,182     8,641  
Total stockholders' equity   349,687     306,738  
Total liabilities, redeemable convertible preferred stock and stockholders' equity $ 501,204   $ 533,001  
       
 
ARTHROCARE CORPORATION
Condensed Consolidated Statements of Operations - Unaudited
(in thousands, except per share data)
 

Three Months Ended

Nine Months Ended

September 30, September 30,
2012 2011 2012 2011
 
Revenues:
Product sales $ 82,602 $ 79,432 $ 258,448 $ 249,864
Royalties, fees and other   4,338     3,835     13,070     12,609  
Total revenues 86,940 83,267 271,518 262,473
 
Cost of product sales   26,204     25,529     80,210     76,170  
 
Gross profit 60,736 57,738 191,308 186,303
Operating expenses:
Research and development 8,184 8,037 23,677 21,460
Sales and marketing 27,175 25,752 86,217 81,124
General and administrative 8,191 9,479 24,833 26,372
Amortization of intangible assets 1,363 1,338 4,000 3,972
Exit costs - 2,814 (778 ) 5,304
Investigation and restatement-related costs   2,139     5,963     4,363     12,145  
Total operating expenses   47,052     53,383     142,312     150,377  
 
Income from operations 13,684 4,355 48,996 35,926
 
Non-operating gains (losses)   183     (1,028 )   (578 )   (661 )
 
Income from continuing operations before income taxes 13,867 3,327 48,418 35,265
 
Income tax provision   3,882     898     13,211     9,677  
 
Net income from continuing operations 9,985 2,429 35,207 25,588
 
Income from discontinued operations, net of taxes   -     -     -     1,911  
 
Net income 9,985 2,429 35,207 27,499
 

Accrued dividend and accretion charges on Series A

3% Redeemable Convertible Preferred Stock   (900 )   (857 )   (2,666 )   (2,546 )
 
Net income available to common stockholders 9,085 1,572 32,541 24,953
 
Other comprehensive income
Foreign currency translation adjustments   951     751     565     365  
 
Total comprehensive income $ 10,936   $ 3,180   $ 35,772   $ 27,864  
 

Weighted average shares outstanding:

Basic 27,714 27,466 27,698 27,335
Diluted 28,087 27,855 28,096 27,755
 
Earnings per share from continuing operations
applicable to common stockholders:
Basic $ 0.27   $ 0.05   $ 0.97   $ 0.70  
Diluted $ 0.27   $ 0.05   $ 0.96   $ 0.68  
 
Earnings per share applicable to common stockholders:
Basic $ 0.27   $ 0.05   $ 0.97   $ 0.75  
Diluted $ 0.27   $ 0.05   $ 0.96   $ 0.74  
             
 
ARTHROCARE CORPORATION
Supplemental Schedule of Product Sales - Unaudited
(in thousands)
   

Three Months Ended

Three Months Ended
September 30, 2012 September 30, 2011
Americas International

Total Product Sales

% Net Product Sales

Americas International

Total Product Sales

% Net Product Sales

 
Sports medicine $ 36,787 $ 18,414 $ 55,201 66.8 % $ 33,251 $ 18,850 $ 52,101 65.6 %
ENT 19,677 5,846 25,523 30.9 % 20,046 4,851 24,897 31.3 %
Other   322   1,556   1,878 2.3 %   658   1,776   2,434 3.1 %
Total product sales $ 56,786 $ 25,816 $ 82,602 100.0 % $ 53,955 $ 25,477 $ 79,432 100.0 %
 
 
 
Nine Months Ended Nine Months Ended
September 30, 2012 September 30, 2011
Americas International

Total Product Sales

% Net Product Sales

Americas International

Total Product Sales

% Net Product Sales

 
Sports medicine $ 113,868 $ 58,357 $ 172,225 66.6 % $ 106,980 $ 58,987 $ 165,967 66.4 %
ENT 62,985 16,629 79,614 30.8 % 62,732 13,903 76,635 30.7 %
Other   1,322   5,287   6,609 2.6 %   2,203   5,059   7,262 2.9 %
Total product sales $ 178,175 $ 80,273 $ 258,448 100.0 % $ 171,915 $ 77,949 $ 249,864 100.0 %




3 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs